

Week	Theme	Lecture (45 mins - 1hr)	Lecturer lead	Practical	Live session
1	Trends and developments in HTA	Introduction to the module.  Mapping out the history and current landscape of HTA across the globe.  Presentations on HTA in various countries	Eleanor Grieve, Senior Lecturer and Manuela Deidda, Research Fellow, HEHTA	Discussion board reflections. Please post your expectations of the course; your experience of HTA in different contexts. Reading list.	
2	Healthcare systems: financing, priority setting and Universal Health Coverage (UHC)	The main financing models of healthcare as a platform for HTA and Universal Health Coverage	Francis Ruiz, LSHTM Eleanor Grieve, Senior Lecturer, HEHTA	Health systems: briefly discuss the healthcare system and financing model of a country of your choice, its progress towards achieving UHC and the role of HTA.	Live Q&A session
3	<b>CHO</b> osing Interventions that are <b>Cost-Effective</b> (CHOICE)	WHO CHOICE and Generalised cost-effectiveness.  Disability Adjusted Life Years (DALYs) Reference Cases.	Eleanor Grieve, Senior Lecturer, HEHTA	Consider the HTA decision for a particular technology in two jurisdictions. Critically discuss factors contributing to any differences in recommendations.	Live Q&A session
4	Assessing Evidence	Review of evidence tools; addressing evidence gaps in Low- and Middle-Income Countries (LMICs).	Robert Heggie, Research Fellow, HEHTA	Read <i>Cost-effectiveness of medical interventions to prevent cardiovascular disease in a sub-Saharan African country – the case of Tanzania</i> (Robberstad et al, 2007) and undertake survey.	
5	Country level cost-effectiveness thresholds	Estimating cost-effectiveness thresholds. Alternative approaches to thresholds in HTA with case studies on: - <i>Norway and differential thresholds</i> - <i>Germany and the efficiency frontier.</i>	Dr Claudia Geue, Senior Lecturer, HEHTA Eleanor Grieve, Senior Lecturer, HEHTA	Read the full report of the first HTA evaluation to be carried out by IQWiG in Germany and critique how well you think the efficiency frontier approach works.	
Reading Week					

6	From cost-effectiveness to budget impact	Budget impact analysis -Australia, New Zealand and UK case study  Costing; WHO One Health Tool	Prof Paula Lorgelly, University of Auckland  Eleanor Grieve, Senior Lecturer, HEHTA	Consider a high value / high cost drug and discuss the budget impact and affordability measures in one or more countries.	
7	Pricing	Value-based, differential and reference pricing and risk sharing agreements  -Taiwan case study	Dr Jasmine Pwu, Ministry of Health and Welfare, Taiwan.  Eleanor Grieve, Senior Lecturer, HEHTA	Case study on the appraisal of Keytruda drug by Pharmac, New Zealand.	
8	Going beyond health - incorporating other elements of social value	Extended cost-effectiveness analysis (ECEA); distributional cost-effectiveness analysis (DCEA).	Dr Andrew Mirelman, World Health Organisation	An exercise on how to incorporate equity in HTA	
9	Priority setting	Value Assessment Frameworks (USA)  Multiple-criteria decision analysis; program budgeting and marginal analysis. -Thailand case study  Stakeholder engagement.	HEHTA colleagues  Eleanor Grieve, Senior Lecturer, HEHTA  Drs Benjarin Santatiwongchai and Saudamini Dabak, HITAP, Thailand	Short opinion piece on the various methods discussed as used in HTA: GCEA, ECEA, DCEA, CBA and MCDA.	
10	Implementation and impact of HTA	Assessing the impact of HTA with illustration of HTA in India	Eleanor Grieve, Senior Lecturer and Manuela Deidda, Research Fellow, HEHTA	Discussion board exercise	Live Q&A session